Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal

Home page

The first global study to assess the extent of pharmaceutical pollution in rivers

The first global study to assess the extent of pharmaceutical pollution in rivers
PRESS RELEASE - Although medicines have improved human health and life expectancy, pharmaceutical residues cause pollution and impact the environment and living organisms. For the first time, a large-scale international study led by the University of York (United Kingdom), in which INRAE and more than 80 other research institutes participated, analysed pollution in 258 rivers in over 100 countries across five continents. Their results, published on February 14th in PNAS, show pharmaceutical contamination in all except three of the rivers studied, with levels that are potentially toxic to aquatic life in a quarter of those sites. The most polluted regions are in developing countries where pharmaceutical manufacturers are located or where wastewater treatment is inadequate.

When we take medicine, the residues are eliminated in wastewater and can end up in our rivers. Medicines are designed to have a precise action on humans, but they have unknown effects on other living organisms (fish and shellfish, microorganisms, plants, etc.) and can upset their biological functions and life cycles. 

The impact of pharmaceutical pollution is well documented in some areas of the world, such as North America, Western Europe and China, but there has never been a global study to determine the situation at a worldwide level. To address this knowledge gap, the University of York launched a vast study in 2018 in conjunction with 86 other institutes around the world to analyse samples from 258 rivers in 104 countries on five continents, including in 36 countries that had never been studied. The study included major rivers such as the Amazon, the Mississippi and the Mekong, with samples taken from sites in regions where modern medicine is not used (for example, a Yanomami village in Venezuela) as well as in some of the planet’s most populated cities, such as New York and Delhi. The samples were analysed for the presence of 61 common pharmaceuticals, including antibiotics, analgesics, anti-inflammatories, antihistamines, diabetes medicines, antidepressants and stimulants (such as caffeine).

Pharmaceutical contamination found in all rivers

During the study, 1052 samples were taken around the globe according to an identical protocol. One laboratory measured the pharmaceutical concentrations to analyse the degree of contamination in the rivers. The scale of the study offers a global view of this contamination, which was found in all the rivers and on all continents, although at varying concentrations and frequencies. The findings show that the degree of pollution in rivers correlates to the socio-economic conditions of the country: the most contaminated sites are lower-middle income countries and associated with areas with little to no infrastructure to treat domestic or pharmaceutical-industry wastewater. Some of the regions that had never before been studied (South America, sub-Saharan Africa and certain parts of southern Asia) are among those with the highest levels of pharmaceutical pollution. For example, researchers found high concentrations of pharmaceuticals in Pakistan (average concentration of 70.8 µg/L, with a maximum measurement of 189 µg/L) and Bolivia (average of 68.9 µg/L, with a maximum of 297 µg/L). The study also found that a quarter of the sites studied had potentially harmful levels of environmental contaminants, including two antibiotics (sulfamethoxazole and ciprofloxacin), an antihistamine (loratadine) and a drug used to treat hypertension (propranolol).

This study made it possible, for the first time, to have a truly representative overview of pharmaceutical pollution in the world’s rivers, including in countries for which little if any information was previously available. In the future, this approach could be applied to study living organisms or other environments such as soils to develop international pollution-monitoring networks.

Reference

John L. Wilkinson et al. Pharmaceutical pollution of the world’s rivers. PNAS February 22, 2022 119 (8) e2113947119; https://doi.org/10.1073/pnas.2113947119

Study conducted as part of the Global Monitoring of Pharmaceuticals Project